Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram
Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
Overall survival and second primary malignancies in men with metastatic prostate cancer
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
ASCO GU 2019: The CHEIRON Study - A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide versus Docetaxel as First-Line Chemotherapy for Patients with mCRPC
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate | Prostate Cancer and Prostatic Diseases
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial - European Urology
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
a Progression-free survival of 63 Japanese patients with... | Download Scientific Diagram
PREVAIL Trial Efficacy and Safety | XTANDI® (enzalutamide) Safety Info
Embarrassment of Riches: Therapies that Improve Overall Survival in mCRPC
Progression-free survival of mCRPC patients treated with AAP | Download Scientific Diagram
View Image
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer - Annals of Oncology
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel? - Clinical Genitourinary Cancer
Overall survival and second primary malignancies in men with metastatic prostate cancer
Visceral Metastases and Prostate Cancer Treatment: 'Die Hard,' 'Tough Neighborhoods,' or 'Evil Humors'?
Clinical Parameters Predict Overall Survival in mCRPC | PracticeUpdate
Overall survival. mCRPC metastatic castration-resistant protate cancer.... | Download Scientific Diagram
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
